Assessment of health state utilities of controlled and uncontrolled psoriasis and atopic eczema: A population-based study

British Journal of Dermatology

Volumn 158, Issue 2, 2008, Pages 351-359

  Schmitt, J ^a   Meurer, M ^a   Klon, M ^a   Frick, K D ^b  

^a UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Atopic eczema; Cost effectiveness analysis; Cost utility analysis; Health utility; Psoriasis vulgaris; Time trade off

Indexed keywords

ANTIINFLAMMATORY AGENT; EMOLLIENT AGENT;

ADULT; ARTICLE; ATOPIC DERMATITIS; CONTROLLED STUDY; CORRELATION ANALYSIS; DEMOGRAPHY; FEMALE; GERMANY; HEALTH ECONOMICS; HEALTH SERVICE; HEALTH STATUS; HUMAN; INTERVIEW; LIFE EXPECTANCY; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PSORIASIS; QUALITY OF LIFE; SOCIOECONOMICS; VISUAL ANALOG SCALE;

ADULT; ATTITUDE TO HEALTH; COST-BENEFIT ANALYSIS; DERMATITIS, ATOPIC; ECONOMICS; FEMALE; GERMANY; HUMANS; MALE; MIDDLE AGED; PSORIASIS;

EID: 38349084979     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2007.08354.x     Document Type: Article

References (35)

1. Russell LB, Gold MR, Siegel JE et al. The role of cost-effectiveness analysis in health and medicine. Panel on Cost-Effectiveness in Health and Medicine. JAMA 1996 276 : 1172 7.
2. Gold MR, Siegel RG, Weinstein MC. Cost-Effectiveness in Health and Medicine. New York : Oxford University Press, 1996.
3. Drummond M, O'Brien B, Stoddart GL et al. Methods for the Economic Evaluation of Health Care Programmes. Toronto, ON : Oxford Medical Publishers, 1998.
4. Torrance G, Feeny D. Utilities and quality-adjusted life years. Int J Technol Assess Health Care 1989 5 : 559 75.
5. Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI) - a simple practical measure for routine clinical use. Clin Exp Dermatol 1994 19 : 210 16.
6. Williams HC. Epidemiology of atopic dermatitis. Clin Exp Dermatol 2000 25 : 522 9.
7. Verboom P, Hakkaart-van Roijen L, Sturkenboom M et al. The cost of atopic dermatitis in the Netherlands: an international comparison. Br J Dermatol 2002 147 : 716 24.
8. Lapidus CS, Kerr PE. Social impact of atopic dermatitis. Med Health RI 2001 84 : 294 5.
9. Naldi L. Epidemiology of psoriasis. Curr Drug Targets Inflamm Allergy 2004 3 : 121 8.
10. Schmitt J, Ford DE. Work limitations and productivity loss are associated with health-related quality of life but not with clinical severity in patients with psoriasis. Dermatology 2006 213 : 102 10.
11. Rapp SR, Feldman SR, Exum ML et al. Psoriasis causes as much disability as other major medical diseases. J Am Acad Dermatol 1999 41 : 401 7.
12. Pitt M, Garside R, Stein K. A cost-utility analysis of pimecrolimus vs. topical corticosteroids and emollients for the treatment of mild and moderate atopic eczema. Br J Dermatol 2006 154 : 1137 46.
13. Woolacott N, Hawkins N, Mason A et al. Etanercept and efalizumab for the treatment of psoriasis: a systematic review. Health Technol Assess 2006 10 : 1 233.
14. Lundberg L, Johannesson M, Silverdahl M et al. Quality of life, health-state utilities and willingness to pay in patients with psoriasis and atopic eczema. Br J Dermatol 1999 141 : 1067 75.
15. Chen SC, Bayoumi AM, Soon SL et al. A catalog of dermatology utilities: a measure of the burden of skin diseases. J Investig Dermatol Symp Proc 2004 9 : 160 8.
16. Meggitt SJ, Gray JC, Reynolds NJ. Azathioprine dosed by thiopurine methyltransferase activity for moderate-to-severe atopic eczema: a double-blind, randomised controlled trial. Lancet 2006 367 : 839 46.
17. Tofte SJ, Graeber M, Cherill R et al. Eczema Area and Severity Index (EASI): a new tool to evaluate atopic dermatitis. J Eur Acad Dermatol Venereol 1998 11 (Suppl. 2 S197.
18. Fredriksson T, Pettersson U. Severe psoriasis - oral therapy with a new retinoid. Dermatologica 1978 157 : 238 44.
19. Lewis V, Finlay AY. 10 years experience of the Dermatology Life Quality Index (DLQI). J Investig Dermatol Symp Proc 2004 9 : 169 80.
20. Hanifin JM, Thurston M, Omoto M et al. The Eczema Area and Severity Index (EASI): assessment of reliability in atopic dermatitis. EASI Evaluator Group. Exp Dermatol 2001 10 : 11 18.
21. Schmitt J, Wozel G. The Psoriasis Area and Severity Index is the adequate criterion to define severity in chronic plaque-type psoriasis. Dermatology 2005 210 : 194 9.
22. Charman C, Williams H. Outcome measures of disease severity in atopic eczema. Arch Dermatol 2000 136 : 763 9.
23. Stata Corporation. Stata Statistical Software : Release 8.0. College Station, TX : Stata Corporation, 2002.
24. Stata Corporation. Stata 8 Reference Manual. College Station, TX : Stata Corporation, 2003.
25. Rosner B. Fundamentals of Biostatistics, 5th edn. Pacific Grove, CA : Duxbury, 2000.
26. Hakkaart-van Roijen L, Verboom P, Redekop WK et al. The cost effectiveness of tapered versus abrupt discontinuation of oral cyclosporin microemulsion for the treatment of psoriasis. Pharmacoeconomics 2001 19 : 599 608.
27. Ellis CN, Reiter KL, Bandekar RR et al. Cost-effectiveness comparison of therapy for psoriasis with a methotrexate-based regimen versus a rotation regimen of modified cyclosporine and methotrexate. J Am Acad Dermatol 2002 46 : 242 50.
28. Ellis CN, Kahler KH, Grueger J et al. Cost effectiveness of management of mild-to-moderate atopic dermatitis with 1% pimecrolimus cream in children and adolescents 2-17 years of age. Am J Clin Dermatol 2006 7 : 133 9.
29. Stein KR, Pearce DJ, Feldman SR. The impact of biologics on the quality of life of psoriasis patients and the economics of psoriasis care. Semin Cutan Med Surg 2005 24 : 52 7.
30. Weinstein MC, Siegel JE, Gold MR et al. Recommendations of the panel on cost-effectiveness in health and medicine. JAMA 1996 276 : 1253 8.
31. Bestehorn K, Biller M, Bredit JG et al. [German recommendations for health care economic evaluation studies. Revised version of the Hannover consensus. Hannover Consensus Group]. Med Klin (Munich) 2000 95 : 52 5.
32. Crott R, Ali F, Burdette-Radoux S. Cost-utility of adjuvant high-dose interferon alpha therapy in stage III cutaneous melanoma in Quebec. Value Health 2004 7 : 423 32.
33. Orme M, Kerrigan J, Tyas D et al. The effect of disease, functional status, and relapses on the utility of people with multiple sclerosis in the UK. Value Health 2007 10 : 54 60.
34. Wildi SM, Cox MH, Clark LL et al. Assessment of health state utilities and quality of life in patients with malignant esophageal dysphagia. Am J Gastroenterol 2004 99 : 1044 9.
35. Zug KA, Littenberg B, Baughman RD et al. Assessing the preferences of patients with psoriasis. A quantitative, utility approach. Arch Dermatol 1995 131 : 561 8.